San Francisco Plastic Surgeon Offers Latisse (TM), a Revolutionary New Product to Enhance Eyelash Growth

Share Article

A prominent San Francisco plastic surgeon weighs in on the newly-touted eyelash growth medication, Latisse, recently released by Allergan. Before Lastisse, limited options were available for actual eyelash growth enhancement, and Dr. Mosser provides advice for getting started with this first-of-its-kind treatment.

I expect it to become a mainstay of eyelash aesthetic treatments in the near future.

As the first Food and Drug Administration-approved prescription treatment of its kind, newly released Latisse has been scientifically proven to promote eyelash growth, according to San Francisco Board-Certified plastic surgeon Dr. Scott Mosser. In light of these recent successes, Dr. Mosser has announced he will begin offering Latisse in San Francisco for patients with reduced eyelash growth or those desiring longer, fuller eyelashes.

Touted as a solution to hypotrichosis, or the condition of diminished eyelash growth, Latisse both lengthens and increases the number of eyelashes in the anagen (growth) phase of the eyelash hair cycle. Utilizing a 0.03% bimatoprost ophthalmic solution, Latisse provides gradual results, with the majority of clinical trial participants seeing significant increases in lash growth and fullness after two months.

"I've been very impressed with the results of this product," said Dr. Mosser. "There are numerous success stories in my practice, from women whose friends think they are wearing eyelash extensions to the woman who ultimately had to trim her lashes so she could wear her sunglasses comfortably."

Lash enhancement is a widespread practice dating back to the Bronze Age in Ancient Egypt. Around 4000 BC, wealthy and noble citizens applied kohl, a mixture of soot and metal, to lashes and brows to bring definition to the eyes. Today, mascara is currently the most popular makeup product used by women, according to a 2008 report by NDP group. About 83 percent of American women report using mascara, compared with only 64 percent who use lipstick.

"A female patient remarked that every woman who uses mascara has been waiting for a product like Latisse," said Mosser. "Most of my patients feel on some level that beautiful lashes are priceless."

Applied once a day to the eyelid with a disposable applicator, Latisse is compatible with mascara use. The cessation of Latisse application results in lashes returning to their previous appearance over the course of several weeks to months.

Before Latisse, those seeking longer lashes not only utilized mascara, but also employed false eyelashes and eyelash extensions. False eyelashes, while relatively inexpensive and easy to apply, have a lifespan of up to one week and are easily prone to separation from the eyelid. Eyelash extensions, while longer lasting at around 2-3 months until the natural lash falls out, are also more expensive in the $200-600 range.

Dr. Mosser does encourage women to acquire this product from certified physician, and only after having a professional evaluation to be sure they are good candidates for Latisse treatment. He maintains that the product has an optimistic future in San Francisco. "Latisse is an excellent product with an established safety record," Mosser said. "I expect it to become a mainstay of eyelash aesthetic treatments in the near future."

Manufactured by Allergan, Inc., Latisse is produced by the biopharmaceutical company also known for Botox® (Botulinum Toxin Type A), Restasis® (cyclosporine ophthalmic emulsion) 0.05%, Lumigan® (bimatoprost ophthalmic solution) 0.03%, Botox® Cosmetic (Botulinum Toxin Type A), the Juvederm family of dermal fillers, and the Lap-Band® Adjustable Gastric Banding System.

Dr. Mosser, whose office is located in San Francisco Union Square's historic 450 Sutter Building, performs various plastic surgery procedures both in his clinic and other Bay Area institutions, including California Pacific Medical Center and St. Mary's Medical Center.


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Scott Mosser

415 398 7778
Email >
Visit website